NBE-Therapeutics develops next-generation antibody-drug conjugates (ADCs) that target solid tumors, aiming to enhance survival rates and improve the quality of life for cancer patients. Their proprietary platform enables the creation of targeted therapies with a long-lasting immune oncology effect, addressing the need for more selective and effective cancer treatments.
Funding
$22M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer treatments lack the precision to target tumors effectively, leading to damage of healthy tissues and reduced quality of life for patients. Existing antibody-drug conjugate (ADC) therapies may not provide a sufficiently long-lasting immune response to eradicate tumors and prevent recurrence.
Solution
NBE-Therapeutics is developing next-generation antibody-drug conjugates (ADCs) designed to selectively target and eradicate solid tumors. Their proprietary platform enables the creation of targeted therapies that aim to enhance survival rates and improve the quality of life for cancer patients. The ADCs are engineered to elicit a long-lasting immune oncology effect, potentially reducing or even eradicating tumors. By focusing on more selective drugs, NBE-Therapeutics seeks to minimize damage to healthy tissues and improve treatment outcomes. Their pipeline includes ADC product candidates in various stages of development, with the goal of entering clinical phases and providing better treatments for cancer patients.
Target Audience
The primary target audience includes cancer patients with solid tumors and the healthcare providers who treat them, specifically oncologists seeking more effective and targeted therapies.
Features
- Proprietary ADC platform for creating targeted therapies against solid tumors
- Designed to elicit a long-lasting immune oncology effect
- Focus on developing highly selective drugs to minimize off-target effects
- Pipeline of ADC product candidates in various stages of development